Sunitinib

N-[2 - (diethylamino ) ethyl] -5 - [( Z) - (5- fluoro-1 ,2 -dihydro -2-oxo -3H- indol-3- ylidene) - methyl] -2,4- dimethyl -1H-pyrrole -3-carboxamide

  • 557795-19-4 (free base)
  • 341031-54-7 ( maleate )

L01XE04

Tyrosine kinase inhibitor

Template: Infobox chemical / molecular formula search available

Sunitinib (trade name: Sutent ®, manufactured by Pfizer) is a receptor tyrosine kinase inhibitor that is unresectable as a drug for treatment of adults with and / or metastatic malignant gastrointestinal stromal tumors ( GIST) is approved if treatment with imatinib due to resistance or intolerance has failed. In addition, the drug used to treat adults with advanced and / or metastatic renal cell carcinoma ( mRCC ) and for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumors ( pNET ) is approved with disease progression in adults.

Pharmacology

Sunitinib inhibits multiple receptor tyrosine kinases. These include the receptors for PDGF, VEGF, c-Kit, FLT, CSF and RET. These receptors are implicated in tumor growth, pathologic angiogenesis and metastatic progression of cancer.

During treatment with sunitinib have the adverse effects fatigue, diarrhea, hand-foot syndrome, stomatitis, and hypertension occur. The cause of the fatigue is often hypothyroidism found to be related to decreased iodine uptake in the thyroid gland is true - probably due to a non- competitive inhibition of thyroid peroxidase.

CAS registry number Anatomical Therapeutic Chemical Classification System Tyrosine-kinase inhibitor Active ingredient Platelet Derived Growth Factor Vascular Endothelial Growth Factor CD117 Journal of the National Cancer Institute Digital Object Identifier The Journal of Clinical Endocrinology and Metabolism
754871
de